Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
56 hedge funds and large institutions have $222M invested in Alpine Immune Sciences Inc in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
6% more funds holding
Funds holding: 53 → 56 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
14% less capital invested
Capital invested by funds: $257M → $222M (-$35.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.91M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.93M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.2M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$321K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$24.7M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$15.5M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.19M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.19M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $11K | – | – | – |
|
52
Citigroup
New York
| $9K | -$23.5K | -2,723 | -72% |
|
|
AIP
53
Ameritas Investment Partners
Lincoln,
Nebraska
| $8K | – | – | – |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | -$16.4K | -1,899 | -73% |
|
55
Fidelity Investments
Boston,
Massachusetts
| $2K | +$2.3K | +266 | New |
|
56
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
FM
57
Frazier Management
Seattle,
Washington
| – | -$24.7M | -1,784,913 | Closed |
|
|
LGM
58
Logos Global Management
San Francisco,
California
| – | -$15.5M | -1,120,000 | Closed |
|
|
ACP
59
Acuta Capital Partners
Redwood City,
California
| – | -$3.19M | -230,000 | Closed |
|
|
WHG
60
Westwood Holdings Group
Dallas,
Texas
| – | -$319K | -23,079 | Closed |
|
|
JF
61
Jump Financial
Chicago,
Illinois
| – | -$175K | -12,600 | Closed |
|
|
WWM
62
Western Wealth Management
Golden,
Colorado
| – | -$171K | -12,360 | Closed |
|
|
PPA
63
Parametric Portfolio Associates
Seattle,
Washington
| – | -$151K | -10,875 | Closed |
|
ALPN Hedge Fund Activity: Q1 2022 in Review
56 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2022, worth a combined $222M — down 14% from $257M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALPN positions and 7 closed out — a net gain of 3 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $2.91M. The largest seller was Frazier Management, exiting entirely with an estimated $24.7M sold.
- 56 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2022, up from 53 in Q4 2021.
- Funds reported $222M of Alpine Immune Sciences Inc stock for Q1 2022, down 14% quarter-over-quarter.
- 10 funds opened new Alpine Immune Sciences Inc positions in Q1 2022 and 7 closed out, a net change of +3 holders.
- The largest Alpine Immune Sciences Inc buyer in Q1 2022 was Paradigm Biocapital Advisors, an estimated $2.91M added.
- The largest Alpine Immune Sciences Inc seller in Q1 2022 was Frazier Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q1 2022.